کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3285172 | 1209222 | 2007 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Significant Enhancement of Esophageal Pre-Epithelial Defense by Tegaserod: Implications for an Esophagoprotective Effect
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
5-HTEGFPGETGFENSGERD5-hydroxytryptamine or serotonin - 5-hydroxytryptamine یا serotoningastroesophageal reflux disease - بیماری ریفلاکس معده به مریtransforming growth factor - تبدیل فاکتور رشدReflux esophagitis - رفلکس ازوفاژیتenteric nervous system - سیستم عصبی روده ایepidermal growth factor - عامل رشد اپیدرمیprostaglandin E - پروستاگلاندین E
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Significant Enhancement of Esophageal Pre-Epithelial Defense by Tegaserod: Implications for an Esophagoprotective Effect Significant Enhancement of Esophageal Pre-Epithelial Defense by Tegaserod: Implications for an Esophagoprotective Effect](/preview/png/3285172.png)
چکیده انگلیسی
Background & Aims: Tegaserod, a serotonin 5-hydroxytryptamine (5-HT)4 receptor agonist, is thought to stimulate intestinal secretions. The aim of the current study was to assess the effect of tegaserod vs placebo on salivary and esophageal protective factors in patients with gastroesophageal reflux disease (GERD). Methods: This study was a randomized, double-blind, placebo-controlled, cross-over trial in 38 GERD patients treated with tegaserod 6 mg twice a day vs placebo. Salivary samples were collected basally and during mastication. In addition, in 32 GERD patients, salivary and esophageal secretions also were collected during infusion of NaCl, HCl/pepsin, and NaCl in a consecutive fashion using a specially designed esophageal catheter. Saliva and esophageal perfusates were assessed for the pH, volume, content of buffers, protein, mucin, epidermal growth factor (EGF), transforming growth factor α (TGFα), and prostaglandin E (PGE)2 and analyzed statistically. Results: Salivary flow rates during administration of tegaserod increased over corresponding values during both basal conditions (P < .01) and mastication (P < .001). The rate of secretion of salivary bicarbonate and nonbicarbonate buffers also increased in basal conditions (P < .001 and P < .01, respectively) and during mastication (P < .05 and P = .05). Salivary EGF increased during mastication (P < .05), whereas PGE2 and TGF α increased in basal conditions (P < .05 and P < .01). Esophageal perfusate volumes increased during administration of tegaserod in basal conditions (P < .05), whereas esophageal EGF secretion increased after mucosal exposure to HCl/pepsin and subsequent final perfusion with NaCl (P < .05). Conclusions: Significant stimulatory impact of 5-HT4 agonist on several salivary protective factors as well as esophageal EGF secretion may have esophagoprotective implications in patients with GERD and may help to address new therapies in the future.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Gastroenterology and Hepatology - Volume 5, Issue 4, April 2007, Pages 430-438
Journal: Clinical Gastroenterology and Hepatology - Volume 5, Issue 4, April 2007, Pages 430-438
نویسندگان
Marek Majewski, Tomasz Jaworski, Irene Sarosiek, Sandra Sostarich, Katherine Roeser, Stanley A. Edlavitch, Jeffrey Kralstein, Grzegorz Wallner, Richard W. McCallum, Jerzy Sarosiek,